Systemic therapy targeted at disrupting DNA damage response (DDR) in solid tumours is attracting attention and it is likely to expand in the coming years. A complex series of checkpoint pathways are recognised to have important roles in the repair of any DNA damage ([@bib28]). This mechanism is mediated through an array of DDR proteins that when activated are involved in arrest of cell cycle to allow DNA repair process to proceed, thus preventing DNA replication and mitosis in the presence of unrepaired damage; otherwise apoptosis or mutagenesis will occur ([@bib8]; [@bib13]). Following DNA damage, sensor multiprotein complexes activate proximal transducers (that is ATM, ATR), which in turn phosphorylate/activate the distal transducers including serine/threonine kinase Checkpoint Kinase 1 (CHK1; [@bib41]; [@bib33]; [@bib20]; [@bib39]; [@bib47]; [@bib13]). Phosphorylated CHK1 (pCHK1) is released to activate the effectors (that is, CDC25) causing their sequestration, degradation or phosphorylation. These combined effects will halt the progression of cell cycle at different phases and are referred to as mobile messenger kinases ([@bib21]; [@bib22]; [@bib13]).

Protein phosphorylation is a well-characterised biochemical process for the reversible regulation of protein activity. In response to DNA damage or replication stress, CHK1 becomes phosphorylated at several C-terminal residues, including the highly conserved S345 and S317 sites ([@bib43]; [@bib37]) and this phosphorylation regulates CHK1 intracellular location ([@bib22]; [@bib23]; [@bib43]). CHK1 appears to function in a cell cycle-dependent manner during at least two phases of the unperturbed cell cycle: S phase and mitosis ([@bib43]).

Previous studies have demonstrated that activated CHK1 and CHK2 phosphorylate a plethora of effectors involved in checkpoints including: effectors that can lead to cell cycle delay (Cdc25A, Cdc25B and p53; [@bib29]; [@bib19]; [@bib49]), DNA repair (BRCA1 and Rad51; [@bib45]; [@bib36]), induction of apoptosis if the damage is irreparable (p53 and E2F1; [@bib2]) and chromatin remodelling (Tousled like kinase1/2; [@bib17]).

DDR checkpoints can be classified generally into two parallel pathways that respond to diverse types of DNA-damaging agents. In the ATM/ATR-CHK1/CHK2-Cdc5s pathway (for reversible and fast response to DNA damage) CHK 1 is regarded as the key distal transducer. The second pathway is the p53-dependent pathway (for irreversible and slower response). In this pathway CHK1/CHK2, with ATM/ATR, phosphorylates p53 or Mdm2 to promote p53 stabilisation ([@bib50]; [@bib13]).

Cancer cells use intact DNA repair mechanisms to evade DNA damage induced by chemotherapy or radiotherapy. Therefore, it was hypothesised that using agents that target DDR proteins including checkpoint kinases can enhance the effect of chemotherapy and radiotherapy and decrease resistance of cancer cells to this treatment modality ([@bib40]). This approach is expected to be more effective in certain subtypes of cancer such as p53-deficient tumours. In normal cells, p53 induces G1 arrest in response to DNA damage, whereas tumour cells that are often p53-deficient are defective in G1 arrest; therefore, cancer cells, unlike normal cells, rely mainly on S or G2 checkpoints that are mediated by CHK1 ([@bib12]). Currently, CHK1 represents one of the most attractive and potential target for anticancer drug development directed against the DDR network ([@bib13]).

The aim of the current study was to investigate the clinical and biological significance of pCHK1 protein expression in BC with particular attention to its role in DDR and response to chemotherapy.

Materials and methods
=====================

The current study was conducted using a consecutive series of 1200 primary operable stage I--III invasive BC that were prepared as a tissue microarray (TMA) from formalin-fixed, paraffin-embedded tissue specimens of patients presented to Nottingham Breast Unit between 1988 and 1998. The age of the patients was less than 70 with a median of 55 years (range 18--70) with a tumour size of less than 5 cm in diameter.

Clinical and pathological data as well as data on a wide range of biomarkers oestrogen receptor (ER)-related genes (ER, progesterone (PgR) and androgen (AR) receptor, GATA3, FOXA1), HER family members (HER1, HER2, HER3 and HER4), DDR proteins (RAD51, BRCA1, BARD1, DNA-PKC*α*, KU70/KU80, UBC9 and ATM), basal (CK5 and CK17) and luminal (CK18) cytokeratin, nuclear transport protein importin subunit alpha-2 (KPNA2; clone Ab84440, Abcam Ltd, Cambridge, UK) used in dilution of 1 : 400 with 60-min incubation; [@bib6]), proliferation and cell cycle-associated proteins (KI67 and p53) and PI3K/AKT pathway proteins (PI3K and AKT) were available. The immunoreactivity, scoring and the optimal cutoff points for these markers were defined as described in the previous studies ([@bib32], [@bib31]; [@bib4], [@bib3]; [@bib7], [@bib5]; [@bib1]).

Data related to outcome including locoregional recurrence, distant metastasis and mortality were collected prospectively. Breast cancer (BC)-specific survival (BCSS) is defined as the time interval in months from the date of the primary surgery until death occurrence due to BC with a median of 129 months (range 4--243 months). Distant metastasis-free survival is defined as duration in months from the primary surgery to the development of distant metastasis with a median of 114 months (range 5--241 months). Patients were managed according to a uniform protocol based on the Nottingham Prognostic Index (NPI) groups, ER and the menopausal status. Patients were offered adjuvant systemic therapy if NPI was \>3.4. If NPI was \>3.4 and ER-positive, endocrine therapy in form of tamoxifen was given, and if the patient was premenopausal Zoladex was added to the previous protocol. A systemic chemotherapy regimen of cyclophosphamide, methotrexate and 5-florouracil (CMF) was used if the patient was ER-negative, provided that the patient was considered fit enough to withstand this regimen. In this series, 25% received chemotherapy and 45% received hormone therapy. None of the patients received anti-HER2-targeted therapy or neoadjuvant therapy.

Immunohistochemistry method
---------------------------

The expression of pCHK1 was investigated in breast tumours using TMA prepared using 0.6-mm cores. Freshly cut 4-*μ*m sections of the TMA were stained using pCHK1 antibody (CHK1phospho-S345; AbCam clone Ab 58567), which is the commonly used biomarker of Chk1 activation ([@bib43]). At first, the slides were heated on a hot plate to 60 °C for 10 min and then deparaffinised in xylene twice for 5 min each. The slides were rehydrated in descending alcohol concentrations and then in water for 5 min. Antigen retrieval was performed by incubating slides in retrieval solution of citrate buffer, pH 6, for 20 min using a microwave. The slides were cooled in cold tap water for 5 min. The immunohistochemical staining was performed using Novocastra Novolink polymer detection kit system (Leica Microsystem, Newcastle, UK) according to the manufacturer\'s instructions. Briefly, hydrogen peroxide was added to block the endogenous peroxidase activity to decrease unwanted background staining. The primary antibody was added at optimum dilution (1 : 150) and incubated for 1 h. After washing the slides, the polymer link was incubated for 30 min. DAB was added for 5 min. Haematoxylin was used as a counterstain for 5 min followed by rinsing in tap water. Finally, the slides were dehydrated in alcohol, cleared in xylene and then cover-slipped using DPX (BDH, Poole, UK).

Scoring of CHK1 in TMA core slides
----------------------------------

Assessment of pCHK1 expression was conducted using a web-based interface (Distiller, Slide path Ltd, Dublin, Ireland) after high-resolution digital-image virtual slides of the stained TMA slides were prepared at × 20 magnification using NanoZoomer (Hamamatsu Photonics, Welwyn Garden City, UK). The scoring method was semiquantitative using a modified histochemical score (*H*-score) that includes both the percentage of the stained cells and the staining intensity. The intensity of staining was scored on a scale of 0--3, where the (0) was referred to negative, (1) referred to weak, whereas the moderate cases were scored as (2) and the strong were scored as (3). Visual estimation was used to determine the percentage of positive cells. The final score is achieved by multiplication of 2 indices and the results range from 0 to 300. Records of pCHK1 expression pattern were visually estimated as nuclear, cytoplasmic or combined nuclear and cytoplasmic staining. The scoring was carried on without previous knowledge of clinical data. Cores with invasive tumours less than 15% were excluded.

Statistical analysis
--------------------

Statistical analysis was performed by using the SPSS IBM 21 statistical software (IBM, New York, NY). The relationship between pCHK1 and different clinicopathological variables was assessed using *χ*^2^-test for categorical data and Mann--Whitney *U*-test for continuous variables. Survival curves were obtained using Kaplan--Meier method for outcome estimation and significance determined using the log-rank test. Multivariate survival analysis was performed using Cox hazard regression model including established prognostic variables significant on univariate analysis. Two-tailed *P*-value less than 0.01 was considered significant in view of multiple comparisons.

Results
=======

Of the whole series, 1079 (90%) cases had sufficient cores to perform scoring. The expression of pCHK1 was detected in the nuclei and cytoplasm of the neoplastic cells ([Figure 1](#fig1){ref-type="fig"}). Nuclear pCHK1 expression was detected in 50% of cases (\>0%) and had a median *H*-score of 29 (range 0--300), whereas cytoplasmic pCHK1 was detected in 94% (\>0%) and had a median *H-*score of 200 (range 0--300). There was a correlation between nuclear and cytoplasmic expression (*P*\<0.0001). For statistical analysis, expression was dichotomised using cutoff points that were selected based on histogram distribution and by the X-tile computer software analysis ([@bib10]) that dichotomises marker expression according to association with outcome. The cutoff points were selected as follows: for nuclear pCHK1, an *H*-score of 20 with 791 out of 1079 (73%) of the cases showing negative/low nuclear expression and for cytoplasmic pCHK1 expression *H*-score of 80 was used with 128 out of 1079 (12%) of the cases showing negative/low expression.

Association with clinicopathological parameters
-----------------------------------------------

Higher nuclear pCHK1 immunohistochemical expression was associated with markers of good prognosis including lower grade with a low proliferation status, smaller size, good NPI and expression of oestrogen receptor-related proteins (ER, PgR, AR, GATA3 and FOXA1). Negative association was seen with triple-negative phenotype and tumours expressing high ki67-labelling index (Ki67LI) and PI3K (*P*\<0.0001). Conversely, cytoplasmic pCHK1 was associated with higher grade with a high proliferation status, poor NPI and lack of expression of ER and PgR. There was a positive association between cytoplasmic expression and triple-negative phenotype, Ki67LI and p53, CK5, AKT and PI3K expression ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}).

Strong correlation was observed between pCHK1 expression with other DDR proteins. There was a positive association between nuclear pCHK1 and expression of homologous recombination (ATM, RAD51 and BRCA1) and sumoylation (PIAS*γ* and nuclear UBC9) markers. Negative association of borderline significance (*P*=0.037) was identified with ATR. Cytoplasmic pCHK1 expression was positively associated with the expression of nonhomologous end-joining markers (KU70/KU80, PIAS*γ*, DNA-PKC*α* and cytoplasmic UBC9) and with the cytoplasmic homologous recombination marker BARD1 ([Table 2](#tbl2){ref-type="table"}).

Regarding subcellular localisation of pCHK1, there was an association between the nuclear transport protein KPNA2 and cytoplasmic/nuclear expression pCHK1. Positive KPNA2 expression was associated with cytoplasmic localisation of the pCHK1 with reduced/negative nuclear expression (nuclear-negative/cytoplasmic-positive phenotype), whereas absence of KPNA2 protein was associated with the lack of cytoplasmic pCHK1 localisation (cytoplasmic negative/nuclear-positive or -negative phenotypes ([Table 3](#tbl3){ref-type="table"}).

Relationship with clinical outcome
----------------------------------

In the whole series, high expression of nuclear pCHK1 showed an association of borderline significance with longer BCSS (*P*=0.018 at 5 years and *P*=0.030 at 15 years of survival). Conversely, high expression of cytoplasmic pCHK1 was associated with shorter BCSS (*P*=0.009 at 5 years and *P*=0.024 at 15 years of survival) as shown in [Figure 2](#fig2){ref-type="fig"}. However, multivariate Cox regression analysis including potential confounding factors of (tumour size, grade, stage, ER and therapy) showed that neither nuclear nor cytoplasmic pCHK1 expression were independent predictors of BCSS (*P*=0.551 and *P*=0.344, respectively). Association with distant metastasis-free interval was not significant (*P*=0.221 and *P*=0.324 for nuclear and cytoplasmic pCHK1, respectively); the data are not shown.

When the cohort was stratified with respect to chemotherapy, a significant association between positive nuclear pCHK1 expression and longer BCSS was found in the subgroup of patients who did not receive chemotherapy (*P*=0.014), whereas for those receiving chemotherapy there was no statistical difference (*P*=0.351; [Figure 3](#fig3){ref-type="fig"}). Further stratification according to the ER status revealed that similar associations were maintained in the ER-positive subgroup with an association between nuclear pCHK1 expression and longer BCSS in chemotherapy-naive patients (*χ*^2^=10.1, *P*=0.001) and no association in chemotherapy-treated patients. Interestingly, in the ER-negative subgroup, the opposite was identified; no association with outcome was observed in chemotherapy-naive patients, whereas among the patients who received chemotherapy longer BCSS was seen in those whose tumours lacked nuclear pCHK1 (*χ*^2^=5.4, *P*=0.021). When triple-negative tumours were selected, an association between the lack of nuclear pCHK1 and better outcome in chemotherapy-treated subgroup was also obtained (*P*=0.043; [Figure 4](#fig4){ref-type="fig"}).

*P-interaction* between pCHK1 and chemotherapy was positive in the whole series (*P*=0.012 (HR=2.4 and 95%CI=1.2--4.7)). When stratified according to ER, *P-interactio*n was significant in the ER-negative subgroup (*P*=0.026 (HR=2.8 and 95% CI=1.1--7.1)) but not in the ER-positive subgroup (*P*=0.226).

Regarding cytoplasmic CHK1, lack of expression showed borderline significance with better BCSS in patients who did not receive chemotherapy (*P*=0.027) but not in those who received chemotherapy (*P*=0.816; [Figure 3](#fig3){ref-type="fig"}).

Discussion
==========

DNA damage is a ubiquitous process, occurring in all nucleated normal cells and, to a higher degree, in neoplastic cells. Sensing of DNA damage is mediated through several distinct complexes of proteins, which are determined by the nature of the DNA lesions and act to catalyse repair ([@bib13]). Formation of repair complexes initiates signalling processes that lead to cell cycle arrest to allow DNA repair without the occurrence of additional DNA replication or cell division. CHK1 is an important protein involved in cell cycle control during DDR and is proposed to be a potential marker that can influence the response of proliferating tumour cells to chemotherapies that damage DNA. In addition, CHK1 inhibitors have emerged as promising novel therapeutic agents ([@bib38]).

This study aimed to investigate pCHK1 protein expression in BC to further understand its role in DDR and whether it is associated with tumour chemotherapy response and therefore could influence patients\' outcome. The expression of pCHK1 was detected in the nucleus and/or in the cytoplasm of the malignant cells. This different subcellular localisation correlated differently with clinicopathological parameters and patients\' outcome. Our results demonstrate that the tumours expressing nuclear pCHK1 feature variables associated with good prognosis including lower grade, lower proliferation status and positivity for hormone receptors. In addition, they express other processes involved in DNA-damage-sensing and homologous recombination DNA-damage repair mechanisms (ATM, RAD51 and BRCA1) and related sumoylation proteins (UBC9 and PIAS*γ*). Downregulation of pCHK1 expression was seen more frequently in tumours with high proliferation status, positive for PI3K and HER2 and in those showing triple-negative phenotype. In contrast, cytoplasmic expression is associated with variables characteristic of poor prognosis including higher grade, high proliferation status, lack of hormone receptors and triple-negative phenotype. Cytoplasmic pCHK1 was associated with non-homologous end-joining markers (KU70/KU80 and DNA-PKC*α*) and with cytoplasmic expression of the homologous recombination (BARD1) and the related sumoylation (UBC9) proteins. Combinatorial expression of nuclear and cytoplasmic expression of pCHK1 revealed that association with good prognostic variables and DDR markers was positive in pure nuclear expression, intermediate in double-negative cases and negative in cases with pure cytoplasmic expression (data not shown). These results may indicate that the cytoplasmic CHK1 protein in BC tissue is not just a form of an aberrant/nonfunctional protein but a protein that may have a function contrasting with that of the functionally normal nuclear localisation of the pCHK1 protein ([@bib42]).

Using immunoblotting and subcellular fractionation techniques, [@bib27]) have detected CHK1 in both the cytoplasm and the nucleus at almost the same level, although its expression is decreased in the cytoplasm in the late S phase. They have found that pCHK1 at S317 is predominantly cytoplasmic in the early S phase and nuclear in the late S phase, whereas the expression of CHK1 phosphorylated at S345 is detected only in the cytoplasmic fraction. The findings of these authors and others ([@bib43]) indicate that not only phosphorylation status but also phosphorylation site can affect subcellular localisation of CHK1. [@bib27]) suggested that pCHK1 at S345, but not at S317, might be important for cytoplasmic localisation of Chk1 during the S phase and that the mobility shift in CHK1, upon DNA damage, was observed only in the cytoplasm and the phosphorylation is critical for signal transducing to downstream target. In fission yeast it was reported that phosphorylation of CHK1 at ser345 appears to be required for checkpoint function, and this phosphorylation increases the pCHK1 in the nucleus through interaction with 14-3-3 protein ([@bib14]). It was also hypothesised that the cytoplasmic expression of CHK1 may have a role in tumorigenesis through the DNA damage sensors and as a transducer for signal pathway, and take this action as a pathway for tumour survival ([@bib8]; [@bib18]); however, further studies are needed to confirm this hypothesis.

The subcellular localisation of CHK1 and the association between aggressive behaviour of cytoplasmic CHK1 in this study may be explained by a defective function of CHK1 in BC. [@bib30]) used a mouse mammary tumour model to study the effect of cytoplasmic CHK1 on genomic instability. They revealed that, at the G2 phase of the cell cycle, CHK1 observed to leave from the nucleus at the time of AKT kinase phosphorylation peak and the reduction of nuclear CHK1 could be explained by the raise of Cdc25A protein noticed in the G2/M phase ([@bib9]). Another possible explanation is that sequestration of cytoplasmic pCHK1 occurs in genomically unstable cells such as PTEN-deficient cells. [@bib30]) have provided evidence that primary BC cells lacking PTEN expression have increased AKT phosphorylation, elevated cytoplasmic CHK1, reduced nuclear location and structural and numerical chromosomal alterations. Therefore, this accumulated cytoplasmic CHK1 occurs in genetically unstable cells that lack an essential tumour suppressor gene ([@bib34]; [@bib46]) that protects the genome stability, hence it is associated with aggressive behaviour tumours, whereas the nuclear type usually occurs in genetically stable cells. In addition, activation of CHK1 occurs in the nucleus; therefore, this nuclear accumulation seems to be of a great importance in the preparation for functional DDR ([@bib16]).

Interestingly, the association between subcellular localisation of CHK1 and the nuclear transport protein KPNA2 may indicate an active process and not just sequestration of an aberrant protein into the cytoplasm. However, these observations are best interpreted when considering the *in vitro* functional studies of the CHK1 protein (see below).

Several studies have investigated CHK1 in BC cell lines, but only a few have investigated CHK1 protein expression in human breast carcinoma. Most of the previous studies used the total CHK1 protein and not the phosphorylated forms. [@bib40]) showed that CHK1 expression was higher in high-grade triple-negative cases. High CHK1 transcript level was associated with tumours of large size, high histological grade and low/absent ER and PgR; however, they did not find a significant association with HER2 or lymph node metastasis. Other authors have demonstrated that high CHK1 expression was positively associated with high-grade and high ki67 level, positive lymph nodes and large tumour size and have regarded CHK1 as a marker of aggressiveness ([@bib24]). However, most of the studies of CHK1 expression in human BC did not consider the phosphorylated form or subcellular localisation of this protein. The exact molecular mechanism that mediates subcellular localisation of the CHK1 protein in BC remains unclear. Some authors suggest that there is continuous shuttling of CHK1 occurring both under normal growth condition ([@bib15]; [@bib16]; [@bib44]) and in response to DNA damage ([@bib14]; [@bib48]; [@bib35]). Under normal growth conditions, CHK1 expression is mainly located in the nucleus ([@bib42]) during the interphase from G1 to G2 phase ([@bib16]). It is also proposed that the phosphorylation of CHK1 by CdK1 is at a site distinct from that activated by ATR (Ser286, Ser301) and triggers Crm-1-dependent nuclear export of CHK1 to mediate cell cycle transition of G2/M phase ([@bib15]). Others propose that activation of CHK1 by ATR-dependent phosphorylation leads to rapid release of CHK1 from the nucleus to the cytoplasm ([@bib48]; [@bib35]). It is also suggested that the phosphorylated form of CHK1 is able to regulate checkpoint protein events both in the cytoplasm and in the nucleus ([@bib36]); for example, in the nucleus there will be activation of Rad51. It was also reported that mono- or diubiquitination promotes CHK1 nuclear exclusion ([@bib22]; [@bib14]; [@bib23]; [@bib43]). These results together with our findings suggest that subcellular localisation of CHK1 is important and is associated with different functions.

Regarding outcome, tumours with nuclear and cytoplasmic pCHK1 expression are associated with longer and shorter survival, respectively; however, this effect was not independent of other prognostic markers assessed in this study in the whole series.

Importantly, the association between nuclear pCHK1 and outcome was different in patients who received or did not receive CMF chemotherapy in our series. This effect was also different between ER-positive and ER-negative tumours, a finding that may reflect the known difference in DDR status between ER-positive and ER-negative BC. In the whole series, an association between positive nuclear pCHK1 expression and longer survival was found in the subgroup of patients who did not receive chemotherapy; however, no such effect was seen in patients who received chemotherapy. The same findings were maintained in the ER-positive subgroup. However, in the ER-negative and triple-negative cohorts, the opposite was identified; no association with outcome was observed in chemotherapy-naive patients, whereas in those patients who received CMF chemotherapy tumour cell expression of nuclear pCHK1 was associated with shorter survival. The association between pCHK1 expression and chemotherapy response in relation to outcome is a reflection of tumour response and was significant in the whole patient series and in the clinically important ER-negative subgroup. These results may indicate that, although positive nuclear pCHK1 is a marker associated with markers of good prognosis and with longer survival in chemotherapy-naive patients, in chemotherapy-treated patients it is associated with reduced survival that may reflect chemoresistance particularly in the ER-negative tumours. These results support the findings of previous studies where an association between chemoresistance and CHK1 expression has been observed ([@bib8]; [@bib21]; [@bib50]; [@bib39]; [@bib40]; [@bib13]; [@bib26]; [@bib11]; [@bib25]). However, in this study, the outcome of patients with tumours expressing cytoplasmic pCHK1 was better when treated with CMF chemotherapy, and further investigation of the interaction between chemotherapy and CHK1 expression and its subcellular localisation is warranted ideally in a randomised clinical trial.

In conclusion, the results of this study emphasise that pCHK1 is an important factor in BC, particularly with respect to DDR and proliferation status, and its subcellular localisation has an impact on the function of the protein. Nuclear pCHK1 was observed to be associated with good prognostic markers and improved survival. In contrast, cytoplasmic expression of pCHK1 is associated with markers of poor prognosis and decreased survival. KPNA2 appears to be involved in CHK1 subcellular localisation. CHK1 has a role in the response of tumours to chemotherapy and subsequently influences outcome. This effect is different between ER-positive and -negative forms of BC. Further study of activating phosphorylation of CHK1, such as phosphorylated ATR and downstream targets such as phosphorylated CDC25A, CDC25B and CDC25C, CDC25A, may help to understand the complex DDR biological processes.
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![**Immunohistochemical expression of CHK1 at × 20.** CHK1 immunostaining for both nuclear and cytoplasmic in **A**--**C** ,whereas in **D** there is weak cytoplasmic staining; the inset refers to the high power. Panel **E** demonstrates only nuclear pCHK1 expression, whereas exclusive cytoplasmic pCHK1 expression appears in **F**.](bjc2014576f1){#fig1}

![**pCHK1 subcellular localisation and outcome.** Kaplan--Meier curve of nuclear (**A**) and cytoplasmic (**B**) pCHK1 expression in the whole series of breast cancer patients with respect to BCSS for 5 years. Kaplan--Meier curve of nuclear (**C**) and cytoplasmic (**D**) pCHK1 expression in the whole series of breast cancer patients with respect to BCSS for 15 years.](bjc2014576f2){#fig2}

![**pCHK1 and outcome with respect to adjuvant chemotherapy.** Kaplan--Meier curve of nuclear pCHK1 in patients who did not receive chemotherapy (**A**) or who received chemotherapy (**B**) with respect to BCSS at 15 years. Panels **C**, **D** represent Kaplan--Meier curve of cytoplasmic pCHK1 in patients without chemotherapy (**C**) or in patient who received chemotherapy (**D**) with respect to BCSS for 15 years.](bjc2014576f3){#fig3}

![**pCHK1 and outcome with respect to adjuvant chemotherapy in the molecular classes.** Panels **A**, **B** represent Kaplan--Meier curve of nuclear pCHK1 in patients who received chemotherapy in ER+ cases with respect to BCSS at 15 years, whereas **C**, **D** for ER---cases. Panel **E** represents Kaplan--Meier curve of nuclear pCHK1 in triple negative patients who received chemotherapy. Abbreviations: Chemo=chemotherapy; TN=triple-negative.](bjc2014576f4){#fig4}

###### Association between nuclear and cytoplasmic CHK1 expression and clinicopathological parameters

                          **Nuclear expression**   **Cytoplasmic expression**                                      
  ---------------------- ------------------------ ---------------------------- -------------- --------- ---------- --------------
  **Age**                                                                                                          
  \<50                           263 (33)                   95 (33)                            41 (32)   317 (33)         
  **⩾**50                        528 (67)                   193 (67)               0.935       87 (68)   633 (67)      0.763
  **Menopause**                                                                                                    
  Pre                            288 (37)                   112 (39)                           45 (35)   355 (37)         
  Post                           502 (63)                   176 (61)               0.464       83 (65)   594 (63)      0.621
  **Size**                                                                                                         
  \<1.5 cm                       369 (47)                   157 (55)                           66 (52)   460 (49)         
  \>1.5 cm                       417 (53)                   131 (45)               0.028       61 (48)   486 (51)      0.479
  **Lymph node stage**                                                                                             
  1                              414 (58)                   156 (64)                           67 (62)   502 (59)         
  2                              244 (34)                   75 (31)                0.221       34 (31)   285 (34)      0.858
  3                               54 (8)                     13 (5)                             7 (7)     60 (7)          
  **Grade**                                                                                                        
  1                              95 (12)                    73 (26)                            26 (20)   142 (15)         
  2                              255 (33)                   107 (37)            **\<0.0001**   61 (48)   301 (32)   **\<0.0001**
  3                              434 (55)                   107 (37)                           40 (32)   500 (53)         
  **Mitotic count**                                                                                                
  1                              226 (30)                   120 (44)                           61 (50)   285 (31)         
  2                              149 (20)                   58 (20)             **\<0.0001**   21 (17)   186 (21)   **\<0.0001**
  3                              384 (51)                   98 (36)                            41 (33)   440 (48)         
  **Stage**                                                                                                        
  1                              456 (58)                   189 (66)                           84 (65)   560 (59)         
  2                              256 (33)                   79 (28)                0.061       34 (27)   301 (32)      0.393
  3                               73 (9)                     19 (6)                            10 (8)     82 (9)          
  **NPI**                                                                                                          
  Good                           194 (26)                   121 (45)                           50 (42)   265 (30)         
  Moderate                       432 (58)                   121 (45)            **\<0.0001**   54 (46)   498 (55)    **0.016**
  Poor                           123 (16)                   29 (10)                            14 (12)   138 (15)         
  **LVI**                                                                                                          
  Negative                       505 (64)                   196 (68)               0.237       85 (67)   615 (65)      0.703
  Positive                       279 (36)                   91 (32)                            42 (33)   328 (35)         

Abbreviations: CHK1=checkpoint kinase1; LVI=lymphovascular invasion; Neg=negative; NPI=Nottingham prognostic index. Bold indicates significant *P*-value (\<0.05).

###### Associations between CHK1 and different proteins

                                                                             **Nuclear CHK1 expression**   **Cytoplasmic CHK1 expression**                                       
  ------------------------------------------------------------------------- ----------------------------- --------------------------------- -------------- ---------- ---------- --------------
  **Oestrogen receptor (ER)-related proteins**                                                                                                                                   
  **ER**                                                                                                                                                                                
   NEG                                                                                230 (29)                         45 (16)               **\<0.0001**   14 (11)    266 (28)   **\<0.0001**
   POS                                                                                556 (71)                        241 (84)                              114 (89)   683 (72)         
  **PgR**                                                                                                                                                                               
   NEG                                                                                346 (45)                         86 (31)               **\<0.0001**   36 (29)    395 (43)    **0.002**
   POS                                                                                426 (55)                         190 (9)                              90 (71)    526 (57)         
  **AR**                                                                                                                                                                                
   NEG                                                                                287 (40)                         72 (28)               **\<0.0001**   35 (31)    323 (38)      0.149
   POS                                                                                424 (60)                        186 (72)                              79 (69)    531 (62)         
  **GATA3**                                                                                                                                                                             
   NEG                                                                                389 (72)                         80 (49)               **\<0.0001**   63 (76)    405 (65)      0.057
   POS                                                                                151 (28)                         83 (51)                              20 (24)    214 (35)         
  **FOXA1**                                                                                                                                                                             
   NEG                                                                                373 (68)                         68 (35)               **\<0.0001**   34 (38)    407 (63)   **\<0.0001**
   POS                                                                                174 (32)                        125 (65)                              55 (62)    243 (37)         
  **HER family proteins**                                                                                                                                                        
  **HER2**                                                                                                                                                                              
   NEG                                                                                658 (86)                        254 (91)                  0.032       111 (90)   800 (87)      0.256
   POS                                                                                110 (14)                         26 (9)                               12 (10)    124 (13)         
  **HER1 (EGFR)**                                                                                                                                                                       
   NEG                                                                                1620 (80)                       230 (81)                  0.544       106 (84)   744 (80)      0.229
   POS                                                                                159 (20)                         53 (19)                              20 (16)    191 (20)         
  **HER3**                                                                                                                                                                              
   NEG                                                                                 44 (6)                          37 (14)               **\<0.0001**   12 (11)     69 (8)       0.289
   POS                                                                                685 (94)                        222 (86)                              99 (89)    807 (92)         
  **HER4**                                                                                                                                                                              
   NEG                                                                                 75 (10)                         53 (19)               **\<0.0001**   26 (22)    102 (11)      0.001
   POS                                                                                696 (90)                        225 (81)                              95 (79)    825 (89)         
  **Triple-negative (TN)**                                                                                                                                                              
   Non-TN                                                                             614 (79)                        251 (90)               **\<0.0001**   115 (90)   750 (81)    **0.009**
   TN                                                                                 160 (21)                         28 (10)                              12 (10)    175 (19)         
  **DNA repair proteins**                                                                                                                                                        
  **ATM**                                                                                                                                                                               
   NEG                                                                                397 (61)                        104 (44)               \<**0.0001**   45 (57)    455 (65)      0.865
   POS                                                                                257 (39)                        135 (56)                              34 (43)    358 (44)         
  **ATR**                                                                                                                                                                               
   NEG                                                                                 267 (8)                        110 (67)                **0.037**     45 (85)    332 (61)      0.719
   POS                                                                                195 (42)                         54 (33)                              32 (42)    216 (39)         
  **RAD51 (nuclear)**                                                                                                                                                                   
   NEG                                                                                426 (63)                         65 (46)                **0.001**     44 (68)    267 (57)      0.107
   POS                                                                                147 (37)                         75 (54)                              21 (32)    200 (43)         
  **BRCA1**                                                                                                                                                                             
   NEG                                                                                128 (20)                         26 (12)                **0.005**     16 (17)    138 (18)      0.757
   POS                                                                                513 (80)                        199 (88)                              80 (83)    631 (82)         
  **BARD1 (cytoplasmic)**                                                                                                                                                               
   NEG                                                                                 64 (12)                         23 (12)                  0.896       22 (28)    65 (10)    **\<0.0001**
   POS                                                                                475 (80)                        162 (88)                              58 (72)    578 (90)         
  **PIAS*****γ***                                                                                                                                                                       
   NEG                                                                                212 (25)                         47 (16)                **0.002**     43 (36)    216 (21)   **\<0.0001**
   POS                                                                                641 (75)                        245 (84)                              75 (64)    810 (79)         
  **KU70/KU80**                                                                                                                                                                         
   NEG                                                                                113 (13)                         41 (14)                  0.690       40 (33)    114 (11)   **\<0.0001**
   POS                                                                                766 (87)                        254 (86)                              83 (67)    936 (99)         
  **DNA-PKC*α***                                                                                                                                                                        
   NEG                                                                                100 (15)                         29 (13)                  0.581       26 (33)    103 (13)   **\<0.0001**
   POS                                                                                553 (85)                        186 (87)                              53 (67)    685 (87)         
  **UBC9 nuclear**                                                                                                                                                                      
   NEG                                                                                387 (55)                         97 (42)               **\<0.0001**   50 (58)    434 (51)      0.258
   POS                                                                                312 (45)                        136 (58)                              36 (42)    411 (49)         
  **UBC9 cytoplasmic**                                                                                                                                                                  
   NEG                                                                                373 (36)                         66 (38)                  0.662       51 (58)    288 (34)   **\<0.0001**
   POS                                                                                486 (64)                        108 (62)                              35 (42)    558 (66)         
  **Cytokeratins (CK)**                                                                                                                                                          
  **CK5**                                                                                                                                                                               
   NEG                                                                                259 (74)                        198 (78)                   0213       87 (93)    702 (73)   **\<0.0001**
   POS                                                                                208 (26)                         56 (22)                               7 (7)     256 (27)         
  **CK17**                                                                                                                                                                              
   NEG                                                                                519 (86)                        180 (90)                  0.074       74 (94)    625 (86)         
   POS                                                                                 88 (15)                         19 (10)                               5 (6)     101 (14)      0.058
  **CK18**                                                                                                                                                                              
   NEG                                                                                111 (16)                         23 (9)                 **0.010**     12 (11)    121 (14)      0.400
   POS                                                                                603 (85)                        232 (91)                              96 (89)    739 (86)         
  **Tumour suppressor, signalling and proliferation-associated proteins**                                                                                                        
  **p53**                                                                                                                                                                               
   NEG                                                                                544 (71)                        208 (74)                  0.248       106 (85)   645 (80)   **\<0.0001**
   POS                                                                                226 (29)                         72 (26)                              19 (15)    279 (30)         
  **KI67**                                                                                                                                                                              
   NEG                                                                               116 (50.9)                       59 (56.7)              **\<0.0001**   61 (54)    335 (34)   **\<0.0001**
   POS                                                                               112 (49.1)                       45 (43.3)                             53 (46)    659 (66)         
  **Akt**                                                                                                                                                                               
   NEG                                                                                131 (22)                         51 (28)                  0.137       36 (40)    146 (21)   **\<0.0001**
   POS                                                                                458 (78)                        134 (72)                              55 (60)    537 (79)         
  **PI3K**                                                                                                                                                                              
   NEG                                                                                146 (22)                         66 (28)                **0.003**     37 (34)    175 (23)    **0.001**
   POS                                                                                510 (78)                         164 72)                              73 (66)    600 (77)         

Abbreviations: AR=androgen; ATM=Ataxia telangiectasia mutated; ATR=Ataxia telangiectasia and Rad3-related protein; BARD1= BRCA1-associated RING domain protein 1; CHK1=checkpoint kinase1; CK=cytokeratin; EGFR=epidermal growth factor; FOXA1=Forkhead box protein A1; NEG=negative, PgR=progesterone; PIAS=protein inhibitor of activated STAT; PI3K= phosphatidylinositide 3-kinases; POS=positive; TN=triple negative. Bold indicates significant *P*-value (\<0.05).

###### The association between KPNA2 expression and CHK1 subcellular localisation

                    **CHK1 nuclear and cytoplasmic expression Number of cases (%)**                                 
  ---------------- ----------------------------------------------------------------- --------- ---------- --------- ----------
  KPNA2 negative                                37 (72)                               19 (73)   225 (49)   94 (68)   \<0.0001
  KPNA2 positive                                14 (28)                               7 (27)    233 (51)   45 (32)       

Abbreviations: CHK1=checkpoint kinase1; cyto=cytoplasmic; KPNA2=karyopherin alpha 2; Nuc=nuclear.

[^1]: These authors contributed equally to this work.
